80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少?

[1]沈惠群,沈松菲.5-Aza-CdR對胃癌中SOX17基因表達的影響[J].福建醫(yī)藥雜志,2024,46(01):24-29.[doi:10.20148/j.fmj.2024.01.007]
點擊復制

5-Aza-CdR對胃癌中SOX17基因表達的影響()
分享到:

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期數(shù):
2024年01期
頁碼:
24-29
欄目:
臨床研究
出版日期:
2024-02-15

文章信息/Info

文章編號:
1002-2600(2024)01-0024-06
作者:
沈惠群1沈松菲2
1 福建醫(yī)科大學附屬漳州市醫(yī)院腫瘤內科,漳州363000;2 福建醫(yī)科大學附屬協(xié)和醫(yī)院腫瘤內科,福州350001
關鍵詞:
胃癌SOX17基因甲基化
分類號:
R735.2
DOI:
10.20148/j.fmj.2024.01.007
文獻標志碼:
A
摘要:
目的檢測胃癌中SOX17的表達情況,探討5-Aza-CdR對胃癌細胞SOX17表達的影響。方法采用免疫組織化學染色(immunohistochmeistry,IHC)法檢測胃癌組織及癌旁組織中SOX17蛋白的表達情況,分析其表達與患者臨床病理參數(shù)的關系。實時定量聚合酶鏈式反應(real-time polymerase chain reaction,Real-time PCR)和蛋白質印跡(Western blot)法檢測胃癌細胞株MGC-803、MKN-45、AGS及正常胃黏膜細胞株GES-1中SOX17基因 mRNA和蛋白的表達情況。甲基化特異性PCR(methylation specific PCR,MSP)法檢測胃癌細胞系SOX17基因啟動子區(qū)甲基化情況。CCK-8法和流式細胞儀分別檢測5-Aza-CdR對AGS細胞增殖和細胞周期的影響。結果與癌旁組織相比,胃癌組織SOX17蛋白陽性表達率明顯降低(癌旁組織80.48% vs.胃癌組織19.51%,P<0.001),與胃癌患者性別、年齡、臨床分期、分化程度、是否伴脈管癌栓無關。SOX17基因mRNA和蛋白在各胃癌細胞系表達明顯降低(P<0.05),且在AGS細胞中表達最低。SOX17基因啟動子區(qū)在AGS和MKN45細胞中均完全甲基化,MGC-803細胞部分甲基化,GES-1細胞完全非甲基化。去甲基化藥物5-Aza-CdR可下調甲基轉移酶的表達,逆轉SOX17基因甲基化,使其mRNA和蛋白表達上調。5-Aza-CdR還可抑制AGS細胞的增殖并使細胞阻滯于G0/G1期。結論5-Aza-CdR可逆轉胃癌細胞SOX17基因甲基化,上調其mRNA和蛋白表達,從而抑制胃癌的發(fā)生發(fā)展。

參考文獻/References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] LIU Y,ASAKURA M,INOUE H,et al.Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells[J].Proc Natl Acad Sci U S A,2007,104(10):3859-3864.
[4] YE Y W,WU J H,WANG C M,et al.Sox17 regulates proliferation and cell cycle during gastric cancer progression[J].Cancer Lett,2011,307(2):124-131.
[5] YIN D,JIA Y,YU Y,et al.SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer[J].Discov Med,2012,14(74):33-40.
[6] HOPMAN A,MOSHI J M,HOOGDUIN K J,et al.SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma[J].Histopathology,2020,76(3):383-393.
[7] JIA Y,YANG Y,ZHAN Q,et al.Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer[J].J Mol Diagn,2012,14(6):577-585.
[8] 郭艷麗,潘盼,郭煒,等.Sox17基因甲基化狀態(tài)與賁門腺癌發(fā)生發(fā)展關系研究[J].中國腫瘤臨床,2012,39(14):965-969.
[9] 楊恒穎,單治理,孫明浩,等.高齡胃癌患者手術治療的短期療效及預后影響因素[J].中國老年學雜志,2019,39(10):2350-2354.
[10] LING Z Q,LV P,LU X X,et al.Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer[J].PLoS One,2013,8(6):e67195.
[11] LING Z Q,GE M H,LU X X,et al.Ndrg2 promoter hypermethylation triggered by helicobacter pylori infection correlates with poor patients survival in human gastric carcinoma[J].Oncotarget,2015,6(10):8210-8225.
[12] DU Y C,OSHIMA H,OGUMA K,et al.Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis[J].Gastroenterology,2009,137(4):1346-1357.
[13] CLARKE R L,YZAGUIRRE A D,YASHIRO-OHTANI Y,et al.The expression of Sox17 identifies and regulates haemogenic endothelium[J].Nat Cell Biol,2013,15(5):502-510.
[14] ZHOU W,WANG K,WANG J,et al.SOX17 inhibits tumor metastasis via Wnt signaling in endometrial cancer[J].Onco Targets Ther,2019,12:8275-8286.
[15] YIN D,JIA Y,YU Y,et al.SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer[J].Discov Med,2012,14(74):33-40.
[16] CHEN H L,CHEW L J,PACKER R J,et al.Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation[J].Cancer Lett,2013,335(2):361-371.
[17] FU D,REN C,TAN H,et al.Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer[J].Medicine(Baltimore),2015,94(11):e637.
[18] LI J Y,HAN C,ZHENG L L,et al.Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma[J].Chin Med J(Engl),2012,125(19):3526-3531.
[19] CHEN Y C,HUANG R L,HUANG Y K,et al.Methylomics analysis identifies epigenetically silenced genes and implies an activation of beta-catenin signaling in cervical cancer[J].Int J Cancer,2014,135(1):117-127.
[20] YE Y W,WU J H,WANG C M,et al. Sox17 regulates proliferation and cell cycle during gastric cancer progression[J].Cancer Lett,2011,307(2):124-131.
[21] FUKAMACHI H,SHIMADA S,ITO K,et al.CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation[J].Cancer Sci,2011,102(7):1313-1321.
[22] 郭艷麗,郭煒,張國強,等.胃癌組織中Sox7、Sox17基因甲基化及臨床意義[J].中國腫瘤,2015,24(7):613-617.
[23] BALGKOURANIDOU I,KARAYIANNAKIS A,MATTHAIOS D,et al.Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer.Association with prognostic variables and survival[J].Clin Chem Lab Med,2013,51(7):1505-1510.
[24] BRECCIA M,SALAROLI A,LOGLISCI G,et al.5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment[J].Leuk Res,2011,35(10):1409-1411.

相似文獻/References:

[1]楊蔡江.胃癌癌組織中p27與cyclinD1的表達及臨床意義[J].福建醫(yī)藥雜志,2017,39(5):50.
[2]陳國平 陳劍明.多項腫瘤標記物在胃癌診斷中的篩選及應用價值[J].福建醫(yī)藥雜志,2019,41(02):4.
 CHEN Guoping,CHEN Jianming..Value of screening and application of multiple combined tumor markers in the diagnosis of gastric cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(01):4.
[3]趙 珅 范南峰 李 惠 劉 捷 俞嘉青 林榕波.阿帕替尼聯(lián)合紫杉醇化療方案治療紫杉醇耐藥的晚期胃癌的臨床研究[J].福建醫(yī)藥雜志,2020,42(01):16.
 ZHAO Shen,FAN Nanfeng,LI Hui,et al.Clinical study of apatinib combined with paclitaxel chemotherapy in the treatment of paclitaxel-resistant advanced gastric cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):16.
[4]呂美玲,賴麗萍,呂冬梅,等.干擾MS4A8對苦參堿抑制胃癌細胞生長的影響[J].福建醫(yī)藥雜志,2023,45(05):98.

備注/Memo

備注/Memo:
基金項目:福建醫(yī)科大學啟航基金(2022QH1276)
通信作者:沈松菲,Email:[email protected]
更新日期/Last Update: 2024-02-15